Gene expression data from pre-treatment melanoma samples revealed immune-related signatures that were highly expressed in patients whose tumors responded to anti-CTLA4 or anti-PD-1 therapy, compared to non-responders (73, 126). The gene discussed is CTLA4; the disease is melanoma.